AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$PFE

DAMICO JENNIFER B. sold $83K of PFE

DAMICO JENNIFER B. (SVP & Controller) sold 3,278 shares of PFIZER INC (PFE) at $25.40 on 2026-08-05.

Original reporting
SEC EDGAR · DAMICO JENNIFER B.
Published Aug 6, 2026, 3:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PFE
Neutral
high confidence
Mentioned
$PFE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

Traders may note insider selling as a sentiment datapoint, but the disclosure lacks any fundamental trigger (no earnings, guidance, deal, or regulatory update).

02

Market read

A routine insider open-market sale is disclosed; it is unlikely to change the investment thesis absent other catalysts.

03

What to watch

The article provides only the sale details, not motivations, tax events, or whether other insiders executed offsetting buys.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-06, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Pfizer.

Company-level read

Ticker impact

$PFENeutralHigh confidence
Context

Pfizer Form 4 shows SVP & Controller Jennifer B. Damico sold 3,278 shares at $25.40 on 2026-08-05, totaling $83,261.20.

Expected impact

Likely minimal near-term impact on PFE price; treat as low-signal insider activity.

Evidence & confidence

The filing discloses a single officer sale size and price, without any accompanying corporate event, guidance change, or regulatory action.

Market effects

Sector

No clear read-through to pharma sector fundamentals from a single officer sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification; absence of a 10b5-1 plan does not automatically imply negative information.

Key entities

  • issuer
    Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Jennifer B. Damico

    SVP & Controller who sold 3,278 shares at $25.40 on 2026-08-05.

Read at source← All news

Related articles

AUG 7
$PFEMed

PFE builds bull case at $26 after earnings beat and insider buys

Pfizer (PFE) shares trade near $26.20 after its Q2 beat on Aug 4. Adjusted EPS was $0.77 vs $0.68 consensus, and revenue was $15.03B vs $14.41B. Pfizer raised 2026 revenue guidance to $60.5B-$62.5B and added $2.5B cost savings (total $9.7B by 2029). Board directors bought about $1M each; bulls cite a base around $24-$26, bears cite patent-cliff revenue risk.

investing.com6 min
AUG 5
$PFEMedAI 8/10

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

Pfizer (PFE) shares fell about 0.5% early despite an earnings beat and a higher revenue outlook. Adjusted EPS was $0.77, above estimates by $0.09. Pfizer announced another $2.5B cost reduction, raising savings through 2029 to $9.7B. Eliquis revenue rose 21% to $2.43B and Padcev rose 23% to $667M. Full-year revenue guidance was raised to $60.5B-$62.5B; adjusted EPS guidance stayed $2.80-$3.00.

yahoo.com4 min
AUG 5
$PFEMed

Pfizer Q2 Earnings Call Highlights

Pfizer’s Q2 earnings call covered COVID vaccine and PAXLOVID revenue sensitivity, margin and expense trends, and a GAAP loss per share of $0.04 driven by $4.3B non-cash impairments. Pfizer raised cost-savings expectations to about $9.7B net through 2029, reported $3.45B operating cash flow, and said it will maintain its dividend. Pipeline updates included PADCEV, prostate and obesity programs.

yahoo.com6 min